Stocks To Watch- Zomato, Tata Power, BHEL, Rail Vikas Nigam, Ajanta Pharma, Spandana Sphoorty Financial
时间:2024-06-26 11:59:03 阅读(143)
Stocks in focus: GIFT Nifty traded 0.01% higher during Thursday’s early trading session at 19,480.5, indicating a flat opening for domestic indices NSE Nifty 50 and BSE Sensex. The equity benchmarks closed flat on Wednesday, paring most intraday gains. Nifty 50 settled higher by 0.02% at 19,347.45 while Sensex gained 65,087.25, higher by 11 points.
“Positive sentiment initially propelled domestic equities, buoyed by softer US labour market data that caused a retreat in US bond yields, alleviating concerns about rate hikes. This positive outlook was reinforced by Chinese banks’ move to reduce existing mortgage rates, favourably impacting Indian metal stocks. However, gains were tempered as the day progressed, primarily due to weakness in global markets attributed to lacklustre economic data from Europe. Banking stocks bore the brunt of this downturn, while mid- and small-cap segments displayed resilience amid the market dynamics,” said Vinod Nair, Head of Research at Geojit Financial Services.
Tata Power Delhi Distribution (Tata Power-DDL) has received a three-year extension till 2026 from the Department of Scientific and Industrial Research (DSIR) for its in-house R&D unit. Tata Power Delhi Distribution is a joint venture between Tata Power and the government of NCT of Delhi.
BHELBharat Heavy Electricals company has won an order for setting up 2×800 MW Supercritical Thermal Power Project Stage-II at Lara in Chhattisgarh through international competitive bidding. The scope of work included designing, engineering, manufacture, supply, construction, erection, testing and commissioning projects with civil and structural works for the EPC project.
RVNLRail Vikas Nigam emerged as the lowest bidder (L1) for a series of projects under the Maharashtra Metro Rail Corporation (Maha Metro) purview. The total consideration for the project is around Rs 256.19 crore.
Ajanta PharmaAjanta Pharma secured final clearance from the United States Food and Drug Administration to market topiramate extended-release capsules in dosages of 25 mg, 50 mg, 100 mg, and 200 mg. This endorsement stems from an agreement with the original developer, positioning Ajanta Pharma for a potential launch of topiramate by or before February 1, 2026.
Spandana Sphoorty FinancialOn Wednesday, a total of four entities chose to sell shares of Spandana Sphoorty Financial for an approximate amount of Rs 268 crore, utilizing open market transactions for the sale. These entities include Valiant Mauritius Partners FDI, Valiant India Opportunities, Valiant Mauritius Partners, and Valiant Mauritius Partners Offshore.
(With agency inputs.)
上一篇:Abans Holdings IPO share allotment- know date, GMP; check how to see status online
下一篇:Year Ender 2023- Why ed-tech startups need to press the reboot button
猜你喜欢
- FII DII data- FPI sold shares worth Rs 628
- FII, DII data- FPIs bought shares worth Rs 2237 cr, DIIs sold shares worth Rs 1196 cr on Thursday, 13 July
- Accenture- Margin headwinds will likely moderate
- 90% traders in F&O segment incur losses- Sebi study
- Markets Wrap-up- Asian stocks mixed, US futures gain; investors weigh China COVID-19 measures, Fed policy
- Accent Microcell’s IPO opens on December 8 with price band between Rs 133–140
- Markets Wrap – Tue, 7 Feb ‘23- Stocks fall, rupee flat; Asia, Europe markets, Gold, Crude, Crypto updates
- F&O watch- Nifty support at 15,700-15,800 for weekly expiry; remain cautious at higher levels in Bank Nifty
- 2023 saw accelerated “formalisation;” MSMEs biggest beneficiaries